Skip to content

Study · Randomized controlled trial · n = 31 · 2015

21 results

Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT Study.

Tsai JN, Uihlein AV, Burnett-Bowie SA, Neer RM, Zhu Y, Derrico N, Lee H, Bouxsein ML, Leder BZ

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Jan 2015Cited by 111 (Europe PMC)

PMID25043459 (opens in a new tab)PMCIDPMC4396184 (opens in a new tab)DOI10.1002/jbmr.2315 (opens in a new tab)PepBankPUB-25043459
Source linkPubMedAsk about this study
Jump to 21 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study21

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, tibial total vBMD did not change with teriparatide.

    In plain wordsIn women with osteoporosis, total shinbone density did not change with teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeTibial total vBMD
    Study

    n = 31

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    In the teriparatide group, total volumetric bone mineral density (vBMD) did not change at either anatomic site but increased in both other groups at both sites.
    1 context sentence
    Summary · context
    at the distal tibia and radius in postmenopausal osteoporotic women randomized to receive teriparatide 20 µg daily (n = 31), denosumab 60 mg every 6 months (n = 33), or both (n = 30) for 12 months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, radial total vBMD did not change with teriparatide.

    In plain wordsIn women with osteoporosis, total forearm bone density did not change with teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeRadial total vBMD
    Study

    n = 31

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    In the teriparatide group, total volumetric bone mineral density (vBMD) did not change at either anatomic site but increased in both other groups at both sites.
    1 context sentence
    Summary · context
    at the distal tibia and radius in postmenopausal osteoporotic women randomized to receive teriparatide 20 µg daily (n = 31), denosumab 60 mg every 6 months (n = 33), or both (n = 30) for 12 months.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, tibial cortical vBMD decreased by 1.6% during teriparatide treatment.

    In plain wordsIn women with osteoporosis, density of the outer shinbone layer decreased during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTibial cortical vBMD
    Study

    n = 31

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg daily · 12 monthsAs given in this study (human).

    Measurements

    Cortical vBMD decrease
    1.6%
    tibia, teriparatide

    Source sentences

    Summary
    Cortical vBMD decreased by 1.6 ± 1.9% at the tibia and by 0.9 ± 2.8% at the radius in the teriparatide group, whereas it increased in both other groups at both sites.
    1 context sentence
    Summary · context
    at the distal tibia and radius in postmenopausal osteoporotic women randomized to receive teriparatide 20 µg daily (n = 31), denosumab 60 mg every 6 months (n = 33), or both (n = 30) for 12 months.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, radial cortical vBMD decreased by 0.9% during teriparatide treatment.

    In plain wordsIn women with osteoporosis, density of the outer forearm bone layer decreased during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseRadial cortical vBMD
    Study

    n = 31

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg daily · 12 monthsAs given in this study (human).

    Measurements

    Cortical vBMD decrease
    0.9%
    radius, teriparatide

    Source sentences

    Summary
    Cortical vBMD decreased by 1.6 ± 1.9% at the tibia and by 0.9 ± 2.8% at the radius in the teriparatide group, whereas it increased in both other groups at both sites.
    1 context sentence
    Summary · context
    at the distal tibia and radius in postmenopausal osteoporotic women randomized to receive teriparatide 20 µg daily (n = 31), denosumab 60 mg every 6 months (n = 33), or both (n = 30) for 12 months.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, cortical thickness did not change during teriparatide treatment.

    In plain wordsIn women with osteoporosis, outer bone thickness did not change during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeCortical thickness
    Study

    n = 31

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Cortical thickness did not change in the teriparatide group but increased in both other groups.
    1 context sentence
    Summary · context
    at the distal tibia and radius in postmenopausal osteoporotic women randomized to receive teriparatide 20 µg daily (n = 31), denosumab 60 mg every 6 months (n = 33), or both (n = 30) for 12 months.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, radial cortical porosity increased by 20.9% during teriparatide treatment.

    In plain wordsIn women with osteoporosis, pores in the outer forearm bone layer increased during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseRadial cortical porosity
    Study

    n = 31

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg daily · 12 monthsAs given in this study (human).

    Measurements

    Cortical porosity change
    20.9%
    radius, teriparatide

    Source sentences

    Summary
    In the teriparatide group, radial cortical porosity increased by 20.9 ± 37.6% and by 5.6 ± 9.9% at the tibia but did not change in the other two groups.
    1 context sentence
    Summary · context
    at the distal tibia and radius in postmenopausal osteoporotic women randomized to receive teriparatide 20 µg daily (n = 31), denosumab 60 mg every 6 months (n = 33), or both (n = 30) for 12 months.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, tibial cortical porosity increased by 5.6% during teriparatide treatment.

    In plain wordsIn women with osteoporosis, pores in the outer shinbone layer increased during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTibial cortical porosity
    Study

    n = 31

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg daily · 12 monthsAs given in this study (human).

    Measurements

    Cortical porosity change
    5.6%
    tibia, teriparatide

    Source sentences

    Summary
    In the teriparatide group, radial cortical porosity increased by 20.9 ± 37.6% and by 5.6 ± 9.9% at the tibia but did not change in the other two groups.
    1 context sentence
    Summary · context
    at the distal tibia and radius in postmenopausal osteoporotic women randomized to receive teriparatide 20 µg daily (n = 31), denosumab 60 mg every 6 months (n = 33), or both (n = 30) for 12 months.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, estimated bone stiffness at both sites did not change during teriparatide treatment.

    In plain wordsIn women with osteoporosis, estimated bone stiffness did not change during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeBone stiffness
    Study

    n = 31

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Bone stiffness and failure load, as estimated by finite element analysis, did not change in the teriparatide group but increased in the other two groups at both sites.
    1 context sentence
    Summary · context
    at the distal tibia and radius in postmenopausal osteoporotic women randomized to receive teriparatide 20 µg daily (n = 31), denosumab 60 mg every 6 months (n = 33), or both (n = 30) for 12 months.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, estimated bone failure load at both sites did not change during teriparatide treatment.

    In plain wordsIn women with osteoporosis, estimated force needed to break bone did not change during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeFailure load
    Study

    n = 31

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Bone stiffness and failure load, as estimated by finite element analysis, did not change in the teriparatide group but increased in the other two groups at both sites.
    1 context sentence
    Summary · context
    at the distal tibia and radius in postmenopausal osteoporotic women randomized to receive teriparatide 20 µg daily (n = 31), denosumab 60 mg every 6 months (n = 33), or both (n = 30) for 12 months.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, combined teriparatide and denosumab increased tibial vBMD more than denosumab alone.

    In plain wordsIn women with osteoporosis, adding teriparatide to denosumab increased shinbone density more than denosumab alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTibial total vBMD versus denosumab
    Study

    n: not reported in source

    Comparator
    Denosumab
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg daily · 12 monthsAs given in this study (human).

    Measurements

    Tibial vBMD change
    3.1%
    combination
    Tibial vBMD change
    2.2%
    denosumab

    Source sentences

    Summary
    The increase in vBMD at the tibia was greater in the combination group (3.1 ± 2.2%) than both the denosumab (2.2 ± 1.9%) and teriparatide groups (-0.3 ± 1.9%) (p < 0.02 for both comparisons).
    1 context sentence
    Summary · context
    at the distal tibia and radius in postmenopausal osteoporotic women randomized to receive teriparatide 20 µg daily (n = 31), denosumab 60 mg every 6 months (n = 33), or both (n = 30) for 12 months.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, combined teriparatide and denosumab increased tibial cortical vBMD more than denosumab alone.

    In plain wordsIn women with osteoporosis, adding teriparatide to denosumab increased outer shinbone density more than denosumab alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTibial cortical vBMD versus denosumab
    Study

    n: not reported in source

    Comparator
    Denosumab alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg daily · 12 monthsAs given in this study (human).

    Measurements

    Cortical vBMD change
    1.5%
    tibia, combination

    Source sentences

    Summary
    Tibia cortical vBMD increased more in the combination group (1.5 ± 1.5%) than both monotherapy groups (p < 0.04 for both comparisons).
    1 context sentence
    Summary · context
    at the distal tibia and radius in postmenopausal osteoporotic women randomized to receive teriparatide 20 µg daily (n = 31), denosumab 60 mg every 6 months (n = 33), or both (n = 30) for 12 months.
  12. 12HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, combined teriparatide and denosumab increased tibial cortical thickness more than denosumab alone.

    In plain wordsIn women with osteoporosis, adding teriparatide to denosumab increased outer shinbone thickness more than denosumab alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTibial cortical thickness versus denosumab
    Study

    n: not reported in source

    Comparator
    Denosumab alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg daily · 12 monthsAs given in this study (human).

    Measurements

    Cortical thickness change
    5.4%
    tibia, combination

    Source sentences

    Summary
    The increase in cortical thickness at the tibia was greater in the combination group (5.4 ± 3.9%) than both monotherapy groups (p < 0.01 for both comparisons).
    1 context sentence
    Summary · context
    at the distal tibia and radius in postmenopausal osteoporotic women randomized to receive teriparatide 20 µg daily (n = 31), denosumab 60 mg every 6 months (n = 33), or both (n = 30) for 12 months.

Studies that did not test the peptide alone9

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 13HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    Combined teriparatide and denosumab increased radial total vBMD in postmenopausal women with osteoporosis.

    In plain wordsIn women with osteoporosis, forearm bone density increased during combined teriparatide and denosumab treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseRadial total vBMD with combination therapy
    Study

    n = 30

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    In the teriparatide group, total volumetric bone mineral density (vBMD) did not change at either anatomic site but increased in both other groups at both sites.
    1 context sentence
    Summary · context
    Because skeletal microstructure and microarchitecture are important components of skeletal integrity, we performed high-resolution peripheral quantitative computed tomography (HR-pQCT) assessments at the distal tibia and radius in postmenopausal osteoporotic women randomized to receive teriparatide…

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 14HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    Combined teriparatide and denosumab increased radial cortical vBMD in postmenopausal women with osteoporosis.

    In plain wordsIn women with osteoporosis, outer forearm bone density increased during combined teriparatide and denosumab treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseRadial cortical vBMD with combination therapy
    Study

    n = 30

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Cortical vBMD decreased by 1.6 ± 1.9% at the tibia and by 0.9 ± 2.8% at the radius in the teriparatide group, whereas it increased in both other groups at both sites.
    1 context sentence
    Summary · context
    Because skeletal microstructure and microarchitecture are important components of skeletal integrity, we performed high-resolution peripheral quantitative computed tomography (HR-pQCT) assessments at the distal tibia and radius in postmenopausal osteoporotic women randomized to receive teriparatide…

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 15HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    Combined teriparatide and denosumab increased cortical thickness in postmenopausal women with osteoporosis.

    In plain wordsIn women with osteoporosis, outer bone thickness increased during combined teriparatide and denosumab treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCortical thickness with combination therapy
    Study

    n = 30

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Cortical thickness did not change in the teriparatide group but increased in both other groups.
    1 context sentence
    Summary · context
    Because skeletal microstructure and microarchitecture are important components of skeletal integrity, we performed high-resolution peripheral quantitative computed tomography (HR-pQCT) assessments at the distal tibia and radius in postmenopausal osteoporotic women randomized to receive teriparatide…

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  4. 16HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    Radial and tibial cortical porosity did not change with combined teriparatide and denosumab in women with osteoporosis.

    In plain wordsIn women with osteoporosis, bone porosity did not change during combined teriparatide and denosumab treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeCortical porosity with combination therapy
    Study

    n = 30

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    In the teriparatide group, radial cortical porosity increased by 20.9 ± 37.6% and by 5.6 ± 9.9% at the tibia but did not change in the other two groups.
    1 context sentence
    Summary · context
    Because skeletal microstructure and microarchitecture are important components of skeletal integrity, we performed high-resolution peripheral quantitative computed tomography (HR-pQCT) assessments at the distal tibia and radius in postmenopausal osteoporotic women randomized to receive teriparatide…

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  5. 17HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    Estimated bone stiffness increased at the radius and tibia with combined teriparatide and denosumab in women with osteoporosis.

    In plain wordsIn women with osteoporosis, estimated bone stiffness increased during combined teriparatide and denosumab treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone stiffness with combination therapy
    Study

    n = 30

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Bone stiffness and failure load, as estimated by finite element analysis, did not change in the teriparatide group but increased in the other two groups at both sites.
    1 context sentence
    Summary · context
    Because skeletal microstructure and microarchitecture are important components of skeletal integrity, we performed high-resolution peripheral quantitative computed tomography (HR-pQCT) assessments at the distal tibia and radius in postmenopausal osteoporotic women randomized to receive teriparatide…

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  6. 18HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    Estimated failure load increased at the radius and tibia with combined teriparatide and denosumab in women with osteoporosis.

    In plain wordsIn women with osteoporosis, estimated bone failure load increased during combined teriparatide and denosumab treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFailure load with combination therapy
    Study

    n = 30

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Bone stiffness and failure load, as estimated by finite element analysis, did not change in the teriparatide group but increased in the other two groups at both sites.
    1 context sentence
    Summary · context
    Because skeletal microstructure and microarchitecture are important components of skeletal integrity, we performed high-resolution peripheral quantitative computed tomography (HR-pQCT) assessments at the distal tibia and radius in postmenopausal osteoporotic women randomized to receive teriparatide…

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  7. 19HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In women with osteoporosis, combined teriparatide and denosumab increased tibial vBMD more than teriparatide alone.

    In plain wordsIn women with osteoporosis, combined teriparatide and denosumab increased shinbone density more than teriparatide alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTibial total vBMD versus teriparatide
    Study

    n: not reported in source

    Comparator
    Teriparatide alone
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Tibial vBMD change
    3.1%
    combination
    Tibial vBMD change
    −0.3%
    teriparatide

    Source sentences

    Summary
    The increase in vBMD at the tibia was greater in the combination group (3.1 ± 2.2%) than both the denosumab (2.2 ± 1.9%) and teriparatide groups (-0.3 ± 1.9%) (p < 0.02 for both comparisons).
    1 context sentence
    Summary · context
    at the distal tibia and radius in postmenopausal osteoporotic women randomized to receive teriparatide 20 µg daily (n = 31), denosumab 60 mg every 6 months (n = 33), or both (n = 30) for 12 months.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  8. 20HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In women with osteoporosis, combined teriparatide and denosumab increased tibial cortical vBMD more than teriparatide alone.

    In plain wordsIn women with osteoporosis, combined teriparatide and denosumab increased outer shinbone density more than teriparatide alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTibial cortical vBMD versus teriparatide
    Study

    n: not reported in source

    Comparator
    Teriparatide alone
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Cortical vBMD change
    1.5%
    tibia, combination

    Source sentences

    Summary
    Tibia cortical vBMD increased more in the combination group (1.5 ± 1.5%) than both monotherapy groups (p < 0.04 for both comparisons).
    1 context sentence
    Summary · context
    at the distal tibia and radius in postmenopausal osteoporotic women randomized to receive teriparatide 20 µg daily (n = 31), denosumab 60 mg every 6 months (n = 33), or both (n = 30) for 12 months.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  9. 21HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In women with osteoporosis, combined teriparatide and denosumab increased tibial cortical thickness more than teriparatide alone.

    In plain wordsIn women with osteoporosis, combined teriparatide and denosumab increased outer shinbone thickness more than teriparatide alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTibial cortical thickness versus teriparatide
    Study

    n: not reported in source

    Comparator
    Teriparatide alone
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Cortical thickness change
    5.4%
    tibia, combination

    Source sentences

    Summary
    The increase in cortical thickness at the tibia was greater in the combination group (5.4 ± 3.9%) than both monotherapy groups (p < 0.01 for both comparisons).
    1 context sentence
    Summary · context
    at the distal tibia and radius in postmenopausal osteoporotic women randomized to receive teriparatide 20 µg daily (n = 31), denosumab 60 mg every 6 months (n = 33), or both (n = 30) for 12 months.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.